Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines

Cytokine

Volumn 60, Issue 3, 2012, Pages 661-666

  Ramakrishnan, Amritha ^a   Althoff, Keri N ^a   Lopez, Joseph A ^a   Coles, Christian L ^a   Bream, Jay H ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cytokine; Influenza; Vaccine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEASONAL INFLUENZA;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERLEUKIN-10; INTERLEUKIN-8; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, ATTENUATED; VACCINES, INACTIVATED; YOUNG ADULT;

TIPULA IRIDESCENT VIRUS;

EID: 84867995082     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.08.004     Document Type: Article

References (45)

1. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363:2036-2044.
2. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59:1-15.
3. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010, 59:1-62.
4. Nakaya H.I., Wrammert J., Lee E.K., Racioppi L., Marie-Kunze S., Haining W.N., et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12:786-795.
5. Sasaki S., Jaimes M.C., Holmes T.H., Dekker C.L., Mahmood K., Kemble G.W., et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007, 81:215-228.
6. Beyer W.E., Palache A.M., de Jong J.C., Osterhaus A.D. Cold-adapted live influenza vaccine vs. inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002, 20:1340-1353.
7. Ohmit S.E., Petrie J.G., Cross R.T., Johnson E., Monto A.S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis 2011, 204:1879-1885.
8. Rappuoli R., Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011, 473:463-469.
9. Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007, 25:6852-6862.
10. Zakay-Rones Z. Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines 2010, 9:1423-1439.
11. Chabalgoity J.A., Baz A., Rial A., Grille S. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev 2007, 18:195-207.
12. Sladkova T., Kostolansky F. The role of cytokines in the immune response to influenza A virus infection. Acta Virol 2006, 50:151-162.
13. Thiel V., Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev 2008, 19:121-132.
14. Porichis F., Kaufmann D.E. HIV-specific CD4 T cells and immune control of viral replication. Curr Opin HIV AIDS 2011, 6:174-180.
15. Wille-Reece U., Wu C.Y., Flynn B.J., Kedl R.M., Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses. J Immunol 2005, 174:7676-7683.
16. Dehqanzada Z.A., Storrer C.E., Hueman M.T., Foley R.J., Harris K.A., Jama Y.H., et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006, 12:478-486.
17. Chang D.H., Osman K., Connolly J., Kukreja A., Krasovsky J., Pack M., et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 2005, 201:1503-1517.
18. Zhu W., Higgs B.W., Morehouse C., Streicher K., Ambrose C.S., Woo J., et al. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 2010, 28:2865-2876.
19. Dabitao D., Margolick J.B., Lopez J., Bream J.H. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the meso scale discovery electrochemiluminescence assay and the cytometric bead array. J Immunol Methods 2011, 372:71-77.
20. Zeman A.M., Holmes T.H., Stamatis S., Tu W., He X.S., Bouvier N., et al. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J 2007, 26:107-115.
21. Beyer W.E., Palache A.M., Sprenger M.J., Hendriksen E., Tukker J.J., Darioli R., et al. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996, 14:1331-1339.
22. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008, 3:e2975.
23. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169:68-76.
24. Subbramanian R.A., Basha S., Shata M.T., Brady R.C., Bernstein D.I. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 2010, 28:8258-8267.
25. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
26. Gelinck L.B., van der Bijl A.E., Beyer W.E., Visser L.G., Huizinga T.W., van Hogezand R.A., et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008, 67:713-716.
27. Quesniaux V.F., Jacobs M., Allie N., Grivennikov S., Nedospasov S.A., Garcia I., et al. TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun 2010, 11:157-179.
28. Agace W.W., Hedges S.R., Ceska M., Svanborg C. Interleukin-8 and the neutrophil response to mucosal gram-negative infection. J Clin Invest 1993, 92:780-785.
29. Witko-Sarsat V., Rieu P., Descamps-Latscha B., Lesavre P., Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000, 80:617-653.
30. Larsen C.G., Anderson A.O., Appella E., Oppenheim J.J., Matsushima K. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989, 243:1464-1466.
31. Jost S., Quillay H., Reardon J., Peterson E., Simmons R.P., Parry B.A., et al. Changes in cytokine levels and NK cell activation associated with influenza. PLoS One 2011, 6:e25060.
32. Gill M.A., Long K., Kwon T., Muniz L., Mejias A., Connolly J., et al. Differential recruitment of dendritic cells and monocytes to respiratory mucosal sites in children with influenza virus or respiratory syncytial virus infection. J Infect Dis 2008, 198:1667-1676.
33. Fritz R.S., Hayden F.G., Calfee D.P., Cass L.M., Peng A.W., Alvord W.G., et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999, 180:586-593.
34. Harris K., Ream R., Gao J., Eichelberger M.C. Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. Virol J 2011, 8:251.
35. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
36. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24:157-160.
37. Wilkinson T.M., Li C.K., Chui C.S., Huang A.K., Perkins M., Liebner J.C., et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012, 18:274-280.
38. Sagnak L., Ersoy H., Ozok U., Senturk B., Ercil H., Bahar G., et al. Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guerin treatment in non-muscle-invasive bladder tumors. Clin Genitourin Cancer 2009, 7:E16-E23.
39. Zuiverloon T.C., Nieuweboer A.J., Vekony H., Kirkels W.J., Bangma C.H., Zwarthoff E.C. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2011.
40. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., et al. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother 2008, 57:1439-1449.
41. Dabitao D., Margolick J.B., Lopez J., Bream J.H. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the meso scale discovery electrochemiluminescence assay and the cytometric bead array. J Immunol Methods 2011.
42. Thakur A., Pedersen L.E., Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012, 30:4907-4920.
43. Moris P., van der Most R., Leroux-Roels I., Clement F., Drame M., Hanon E., et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011, 31:443-454.
44. Hillaire M.L., van Trierum S.E., Kreijtz J.H., Bodewes R., Geelhoed-Mieras M.M., Nieuwkoop N.J., et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol 2011, 92:2339-2349.
45. Wagar L.E., Rosella L., Crowcroft N., Lowcock B., Drohomyrecky P.C., Foisy J., et al. Humoral and cell-mediated immunity to pandemic H1N1 influenza in a Canadian cohort one year post-pandemic: implications for vaccination. PLoS One 2011, 6:e28063.